A Phase 3 interventional study of Boceprevir and Peg-interferon alfa-2b in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing boceprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. boceprevir · Hepatitis C, Chronic.
Among the 20 studies testing boceprevir in Hepatitis C, Chronic, this one is the 9th largest by enrollment, is one of 5 that started in 2013, is one of 12 in phase 3, and was the 19th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 20 studies testing boceprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
boceprevir: first FDA approval 2011 (VICTRELIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 13 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 257 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 239 across the 20 interventional studies. Of the 15 that completed or were terminated, 14 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 21st largest by enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2013, is one of 32 in phase 3, and was the 102nd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing boceprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the difference in the efficacy between a 16-week treatment regimen of boceprevir (BOC) in combination with peg-intron alpha 2b (P) plus ribavirin (R) (BOC + PR) and a 28-week treatment regimen of BOC + PR in previously untreated participants with chronic hepatitis C (CHC) genotype 1 in Asia who achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin
All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin
All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
Drug: Boceprevir · Biological: Peg-interferon alfa-2b · Drug: Ribavirin
800 mg three times daily orally
Also known as: MK-3034
1.5 mcg/kg weekly subcutaneously
Also known as: PegIntron
800-1400 mg twice-daily divided orally based on body weight
Also known as: Rebetol
Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]
SVR12 was declared when participants who had undetectable HCV RNA (HCV RNA \< Lower Limit of Quantification \[LLoQ\]) after the 12-week lead-in also had undetectable HCV RNA 12 weeks after completing their assigned BOC treatment regimen. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
Time frame: Follow-up Week (FW) 12 (up to 40 weeks)
Percentage of Participants With Undetectable HCV RNA Across Treatment
The percentage of participants with undetectable HCV RNA (HCV RNA \<LLoQ) at TW4, TW8, and TW12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
Time frame: TW4, TW8, and TW12
Percentage of Participants Achieving SVR12 Among Participants With Undetectable HCV RNA Across Treatment
The percentage of participants achieving SVR12 who had undetectable HCV RNA (HCV RNA \<LLoQ) at Week 4, Week 8, and Week 12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
Time frame: TW4, TW8, and TW12
Percentage of Participants With Relapse
The percentage of viral relapse (defined as confirmed HCV RNA \>15 IU/mL after End-of-Treatment \[EOT\]) among participants who had undetectable HCV RNA at EOT was determined for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
Time frame: From EOT to FW12 (up to 12 weeks)
Percentage of Participants With Neutropenia
The percentage of participants with neutropenia (neutrophil count \<0.75 x10\^9/L) is summarized for each arm.
Time frame: Up to 60 weeks
Percentage of Participants With Anemia
The percentage of participants with anemia (hemoglobin \[Hgb\] \<10 g/dL) was determined in each arm.
Time frame: Up to 60 weeks
Percentage of Participants With Dose Discontinuation Due to Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The percentage of participants who discontinued from BOC, BOC + RBV, or all medications due to an AE are reported.
Time frame: From TW1 through TW48
Percentage of Participants With Treatment-Related Serious AEs (SAEs)
A SAE is any AE that results in death, is life threatening, results in persistent or significant disability, results in or prolongs an existing inpatient hospitalization, is a congenital birth defect, is a cancer, is associated with an overdose, or is another important medical event.
Time frame: Up to 60 weeks
Treatment-naïve adult male and female participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection were recruited in the Asia-Pacific region.
| Milestone | All Treated Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|---|
| Started | 257 | 0 | 0 | 0 |
| Completed | 236 | 0 | 0 | 0 |
| Not completed | 21 | 0 | 0 | 0 |
| Milestone | All Treated Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|---|
| Started | 0 | 102 | 105 | 29 |
| Completed | 0 | 97 | 97 | 23 |
| Not completed | 0 | 5 | 8 | 6 |
SVR12 was declared when participants who had undetectable HCV RNA (HCV RNA \< Lower Limit of Quantification \[LLoQ\]) after the 12-week lead-in also had undetectable HCV RNA 12 weeks after completing their assigned BOC treatment regimen. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm] | 70.6 | 81.9 | — |
The percentage of participants with undetectable HCV RNA (HCV RNA \<LLoQ) at TW4, TW8, and TW12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| TW4 | 24.8 | 17.1 | 0.0 |
| TW8 | 100.0 | 100.0 | 0.0 |
| TW12 | 99.0 | 100.0 | 69.0 |
The percentage of participants achieving SVR12 who had undetectable HCV RNA (HCV RNA \<LLoQ) at Week 4, Week 8, and Week 12 is summarized for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| % Undetectable HCV RNA at TW4 (n=25, 18, 0) | 24.5 | 14.3 | 0.0 |
| % Undetectable HCV RNA at TW8 (n=101, 104, 0) | 69.6 | 81.0 | 0.0 |
| % Undetectable HCV RNA at TW12 (n=100, 103, 20) | 68.6 | 80.0 | 41.4 |
The percentage of viral relapse (defined as confirmed HCV RNA \>15 IU/mL after End-of-Treatment \[EOT\]) among participants who had undetectable HCV RNA at EOT was determined for each arm. The Roche COBAS™ Taqman™ automated HCV test (v2.0 assay) used in this study has a LLoQ of 15 IU/mL.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Percentage of Participants With Relapse | 20.4 | 1.1 | 0.0 |
The percentage of participants with neutropenia (neutrophil count \<0.75 x10\^9/L) is summarized for each arm.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Percentage of Participants With Neutropenia | 10.8 | 12.4 | 4.0 |
The percentage of participants with anemia (hemoglobin \[Hgb\] \<10 g/dL) was determined in each arm.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Percentage of Participants With Anemia | 33.3 | 43.8 | 26.0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The percentage of participants who discontinued from BOC, BOC + RBV, or all medications due to an AE are reported.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Discontinued from BOC | 2.9 | 7.6 | 16.0 |
| Discontinued from BOC + R | 0.0 | 5.7 | 8.0 |
| Discontinued from all Study Medication | 0.0 | 5.7 | 8.0 |
A SAE is any AE that results in death, is life threatening, results in persistent or significant disability, results in or prolongs an existing inpatient hospitalization, is a congenital birth defect, is a cancer, is associated with an overdose, or is another important medical event.
| Percentage of Participants | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| Percentage of Participants With Treatment-Related Serious AEs (SAEs) | 2.9 | 3.8 | 4.0 |
Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: 16-week Treatment Arm | — | 9/102 (8.8%) | 96/102 (94.1%) |
| Arm 2: 28-week Treatment Arm | — | 6/105 (5.7%) | 98/105 (93.3%) |
| Arm 3: 48-week Treatment Arm | — | 4/50 (8%) | 46/50 (92%) |
| Event | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/102 | 2/105 | 1/50 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/102 | 0/105 | 1/50 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 0/105 | 1/50 |
| DepressionPsychiatric disorders | 0/102 | 0/105 | 1/50 |
| NeutropeniaBlood and lymphatic system disorders | 1/102 | 0/105 | 0/50 |
| IleusGastrointestinal disorders | 1/102 | 0/105 | 0/50 |
| VomitingGastrointestinal disorders | 1/102 | 0/105 | 0/50 |
| PyrexiaGeneral disorders | 1/102 | 0/105 | 0/50 |
| Biliary dilatationHepatobiliary disorders | 1/102 | 0/105 | 0/50 |
| PneumoniaInfections and infestations | 1/102 | 0/105 | 0/50 |
| Event | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 33/102 | 44/105 | 12/50 |
| PyrexiaGeneral disorders | 23/102 | 23/105 | 17/50 |
| AlopeciaSkin and subcutaneous tissue disorders | 23/102 | 34/105 | 8/50 |
| Decreased appetiteMetabolism and nutrition disorders | 18/102 | 24/105 | 12/50 |
| DizzinessNervous system disorders | 17/102 | 25/105 | 9/50 |
| MyalgiaMusculoskeletal and connective tissue disorders | 23/102 | 22/105 | 7/50 |
| NauseaGastrointestinal disorders | 16/102 | 15/105 | 11/50 |
| DysgeusiaNervous system disorders | 15/102 | 23/105 | 8/50 |
| HeadacheNervous system disorders | 17/102 | 18/105 | 8/50 |
| RashSkin and subcutaneous tissue disorders | 8/102 | 18/105 | 4/50 |
The total number of participants in Arm 3 (i.e., n=50) includes participants who completed the BOC + PR lead-in and were allocated at Week 12 based on having detectable HCV RNA (n=29), as well as participants who began the BOC + PR lead-in but discontinued prior to Week 12 (n=21).
| Age, Continuous(Years) | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm | Total |
|---|---|---|---|---|
| Mean | 44.1 ± 11.1 | 44.6 ± 10.6 | 46.5 ± 11.8 | 44.8 ± 11.0 |
| Sex: Female, Male(Participants) | Arm 1: 16-week Treatment Arm | Arm 2: 28-week Treatment Arm | Arm 3: 48-week Treatment Arm | Total |
|---|---|---|---|---|
| Female | 43 | 41 | 24 | 108 |
| Male | 59 | 64 | 26 | 149 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Oct 2013 to primary completion in Aug 2015, 21 months.
Results were first posted in Nov 2016, 1 year 3 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Boceprevir · Peginterferon alfa-2b · Ribavirin